MSD’s Phase IIb study of tulisokibart achieves primary endpoint
The trial demonstrated that both high- and medium-dose regimens achieved superiority over placebo at week 16.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance